[Federal Register Volume 62, Number 35 (Friday, February 21, 1997)] [Notices] [Pages 8025-8026] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 97-4228] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES [Docket No. 97M-0054] Schneider (USA), Inc.; Premarket Approval of WALLSTENT Iliac Endoprosthesis
Agency
Food and Drug Administration, HHS.
Action
Notice.
-----------------------------------------------------------------------
Summary
The Food and Drug Administration (FDA) is announcing its approval of the application by Schneider (USA), Inc., Minneapolis, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the WALLSTENT Iliac Endoprosthesis. After reviewing the recommendation of the Circulatory System Devices Panel, FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 28, 1996, of the approval of the application. In addition, the WALLSTENT Iliac Endoprosthesis requires tracking under the act as amended by the Safe Medical Devices Act of 1990.
Dates
Petitions for administrative review by March 24, 1997.
Addresses
Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
For Further Information Contact
Judy J. Danielson, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8243.
Supplementary Information
On June 9, 1994, Schneider (USA), Inc., Minneapolis, MN 55432, submitted to CDRH an application for premarket approval of the WALLSTENT Iliac Endoprosthesis. The device is a peripheral stent and is indicated for use following suboptimal percutaneous transluminal angioplasty (PTA) of common and/or external iliac artery stenotic lesions, which are less than or equal to 10 centimeters in length. A suboptimal PTA is defined as a technically successful dilation, judged by the physician to be suboptimal due to the presence of unfavorable lesion morphology such as: An inadequate angiographic and/or hemodynamic result as defined by a 30 percent or greater residual stenosis after PTA, lesion recoil, or intimal flaps; flow limiting dissections post PTA longer than the initial lesion length; or a 5 mmHg or greater mean transtenotic pressure gradient post PTA.
On March 4, 1996, the Circulatory System Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, reviewed and recommended approval of the application. On May 28, 1996, CDRH approved the application by a letter to the applicant from the Director of the Office of Device Evaluation, CDRH. A summary of the safety and effectiveness data on which CDRH based its approval is on file in the Dockets Management Branch (address above) and is available from that office upon written request. Requests should be identified with the name of the device and the docket number found in brackets in the heading of this document. Under section 519(e) of the act (21 U.S.C. 360i(e)) as amended by the Safe Medical Devices Act of 1990, manufacturers of certain types of devices are required to adopt a method of tracking that follows the devices through the distribution chain and then identifies and follows the patients who receive them. FDA has identified the above device as a new generic type of device requiring tracking. FDA is providing a 30- day period for interested persons to submit to the Dockets Management Branch (address above) written comments regarding the agency's position that this new generic type of device requires tracking.
Opportunity for Administrative Review
Section 515(d)(3) of the act (21 U.S.C. 360e(d)(3)) authorizes any interested person to petition, under section 515(g) of the act, for administrative review of CDRH's decision to approve this application. A petitioner may request either a formal hearing under part 12 (21 CFR part 12) of FDA's administrative practices and procedures regulations or a review of the application and CDRH's action by an independent advisory committee of experts. A petition is to be in the form of a petition for reconsideration under 21 CFR 10.33(b). A petitioner shall identify the form of review requested (hearing or independent advisory committee) and shall submit with the petition supporting data and information showing that there is a genuine and substantial issue of material fact for resolution through administrative review. After reviewing the petition, FDA will decide whether to grant or deny the petition and will publish a notice of its decision in the Federal Register. If FDA grants the petition, the notice will state the issue to be reviewed, the form of the review to be used, the persons who may participate in the review, the time and place where the review will occur, and other details. Petitioners may, at any time on or before March 24, 1997, file with the Dockets Management Branch (address above) two copies of each petition and supporting data and information, identified with the name of the device and the docket number found in brackets in the heading of this document. Received petitions may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. This notice is issued under the Federal Food, Drug, and Cosmetic Act (secs. 515(d), 520(h), (21 U.S.C. 360e(d), 360j(h))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Director, Center for Devices and Radiological Health (21 CFR 5.53).
Dated: January 16, 1997. Joseph A. Levitt, Deputy Director for Regulations Policy, Center for Devices and Radiological Health. [FR Doc. 97-4228 Filed 2-20-97; 8:45 am] BILLING CODE 4160-01-F